Pesquisa | BVS Violência e Saúde

1.

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.

Peyrin-Biroulet, Laurent; Arkkila, Perttu; Armuzzi, Alessandro; Danese, Silvio; Ferrante, Marc; Jahnsen, Jørgen; Louis, Edouard; Lukás, Milan; Reinisch, Walter; Roblin, Xavier; Smith, Philip J; Kwon, Taek; Kim, Jeeyoung; Yoon, Sangwook; Kim, Dong-Hyeon; Atreya, Raja.

BMC Gastroenterol ; 24(1): 121, 2024 Mar 27.

Artigo em Inglês | MEDLINE | ID: mdl-38539103

2.

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.

Pauwels, Renske W M; van der Woude, C Janneke; Nieboer, Daan; Steyerberg, Ewout W; Casanova, María J; Gisbert, Javier P; Kennedy, Nick A; Lees, Charlie W; Louis, Edouard; Molnár, Tamás; Szántó, Kata; Leo, Eduardo; Bots, Steven; Downey, Robert; Lukas, Milan; Lin, Wei C; Amiot, Aurelien; Lu, Cathy; Roblin, Xavier; Farkas, Klaudia; Seidelin, Jakob B; Duijvestein, Marjolijn; D'Haens, Geert R; de Vries, Annemarie C.

Clin Gastroenterol Hepatol ; 20(8): 1671-1686.e16, 2022 08.

Artigo em Inglês | MEDLINE | ID: mdl-33933376

3.

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Peyrin-Biroulet, Laurent; Arkkila, Perttu; Armuzzi, Alessandro; Danese, Silvio; Guardiola, Jordi; Jahnsen, Jørgen; Lees, Charles; Louis, Edouard; Lukás, Milan; Reinisch, Walter; Roblin, Xavier; Jang, Minyoung; Byun, Han Geul; Kim, Dong-Hyeon; Lee, Sung Jeong; Atreya, Raja.

BMC Gastroenterol ; 22(1): 291, 2022 Jun 08.

Artigo em Inglês | MEDLINE | ID: mdl-35676620

4.

Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques.

Lukas, Martin; Kolar, Martin; Ryska, Ondrej; Juhas, Stefan; Juhasova, Jana; Kalvach, Jaroslav; Pazin, Jaroslav; Kocisova, Tereza; Foltan, Ondrej; Kristianova, Hana; Ptacnik, Jan; Vitkova, Ivana; Bortlik, Martin; Lukas, Milan.

Gastrointest Endosc ; 93(1): 250-256, 2021 01.

Artigo em Inglês | MEDLINE | ID: mdl-32535192

5.

A novel postgraduate endoscopic course using a large animal model of secondary Crohn's disease stricture.

Lukas, Martin; Kolar, Martin; Ryska, Ondrej; Juhas, Stefan; Juhasova, Jana; Kalvach, Jaroslav; Pazin, Jaroslav; Kocisova, Tereza; Foltan, Ondrej; Kristianova, Hana; Ptacnik, Jan; Vitkova, Ivana; Bortlik, Martin; Lukas, Milan.

Surg Endosc ; 35(6): 3199-3204, 2021 06.

Artigo em Inglês | MEDLINE | ID: mdl-33661380

6.

Treating inflammatory bowel diseases in the 21st century: individualized therapy and telemedicine.

Lukás, Milan.

Vnitr Lek ; 67(4): 201-205, 2021.

Artigo em Inglês | MEDLINE | ID: mdl-34275304

7.

Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?

Malickova, Karin; Kratka, Zuzana; Luxova, Stepanka; Bortlik, Martin; Lukas, Milan.

Scand J Gastroenterol ; 55(8): 917-919, 2020 08.

Artigo em Inglês | MEDLINE | ID: mdl-32663041

8.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel, Jean-Frederic; Panaccione, Remo; Bossuyt, Peter; Lukas, Milan; Baert, Filip; Vanásek, Tomas; Danalioglu, Ahmet; Novacek, Gottfried; Armuzzi, Alessandro; Hébuterne, Xavier; Travis, Simon; Danese, Silvio; Reinisch, Walter; Sandborn, William J; Rutgeerts, Paul; Hommes, Daniel; Schreiber, Stefan; Neimark, Ezequiel; Huang, Bidan; Zhou, Qian; Mendez, Paloma; Petersson, Joel; Wallace, Kori; Robinson, Anne M; Thakkar, Roopal B; D'Haens, Geert.

Lancet ; 390(10114): 2779-2789, 2017 12 23.

Artigo em Inglês | MEDLINE | ID: mdl-29096949

9.

Therapy for peptic ulcer disease.

Lukás, Milan.

Vnitr Lek ; 64(6): 595-599, 2018.

Artigo em Inglês | MEDLINE | ID: mdl-30223656

10.

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Regueiro, Miguel; Feagan, Brian G; Zou, Bin; Johanns, Jewel; Blank, Marion A; Chevrier, Marc; Plevy, Scott; Popp, John; Cornillie, Freddy J; Lukas, Milan; Danese, Silvio; Gionchetti, Paolo; Hanauer, Stephen B; Reinisch, Walter; Sandborn, William J; Sorrentino, Dario; Rutgeerts, Paul.

Gastroenterology ; 150(7): 1568-1578, 2016 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-26946343

11.

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.

Kolar, M; Duricova, D; Bortlik, M; Hruba, V; Machkova, N; Mitrova, K; Malickova, K; Lukas, M; Lukas, Milan.

Dig Dis ; 35(1-2): 91-100, 2017.

Artigo em Inglês | MEDLINE | ID: mdl-28147356

12.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn, William J; Feagan, Brian G; Rutgeerts, Paul; Hanauer, Stephen; Colombel, Jean-Frédéric; Sands, Bruce E; Lukas, Milan; Fedorak, Richard N; Lee, Scott; Bressler, Brian; Fox, Irving; Rosario, Maria; Sankoh, Serap; Xu, Jing; Stephens, Kristin; Milch, Catherine; Parikh, Asit.

N Engl J Med ; 369(8): 711-21, 2013 Aug 22.

Artigo em Inglês | MEDLINE | ID: mdl-23964933

13.

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.

Bortlik, Martin; Duricova, Dana; Machkova, Nadezda; Hruba, Veronika; Lukas, Martin; Mitrova, Katarina; Romanko, Igor; Bina, Vladislav; Malickova, Karin; Kolar, Martin; Lukas, Milan.

Scand J Gastroenterol ; 51(2): 196-202, 2016.

Artigo em Inglês | MEDLINE | ID: mdl-26329773

14.

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.

Malícková, Karin; Duricová, Dana; Bortlík, Martin; Hind'os, Miroslav; Machková, Nadezda; Hrubá, Veronika; Lukás, Martin; Zima, Tomás; Lukás, Milan.

Biologicals ; 44(1): 33-6, 2016 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-26603635

15.

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.

Danese, Silvio; Rudzinski, Janusz; Brandt, Wolfgang; Dupas, Jean-Louis; Peyrin-Biroulet, Laurent; Bouhnik, Yoram; Kleczkowski, Dariusz; Uebel, Peter; Lukas, Milan; Knutsson, Mikael; Erlandsson, Fredrik; Hansen, Mark Berner; Keshav, Satish.

Gut ; 64(2): 243-9, 2015 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-25304132

16.

Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.

Juzlova, Katerina; Votrubova, Jana; Kacerovska, Denisa; Lukas, Milan; Bortlik, Martin; Rohacova, Hana; Nohynkova, Eva; Vojackova, Nadezda; Fialova, Jorga; Hercogova, Jana.

Dermatol Ther ; 27(3): 131-4, 2014.

Artigo em Inglês | MEDLINE | ID: mdl-24903470

17.

[Etiology and pathogenesis of inflammatory bowel diseases]. / Etiologie a patogeneze idiopatických strevních zánetu

Lukás, Milan.

Vnitr Lek ; 60(7-8): 640-4, 2014.

Artigo em Tcheco | MEDLINE | ID: mdl-25130643

18.

Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.

Cleynen, Isabelle; González, Juan R; Figueroa, Carolina; Franke, Andre; McGovern, Dermot; Bortlík, Martin; Crusius, Bart J A; Vecchi, Maurizio; Artieda, Marta; Szczypiorska, Magdalena; Bethge, Johannes; Arteta, David; Ayala, Edgar; Danese, Silvio; van Hogezand, Ruud A; Panés, Julian; Peña, Salvador Amado; Lukas, Milan; Jewell, Derek P; Schreiber, Stefan; Vermeire, Severine; Sans, Miquel.

Gut ; 62(11): 1556-65, 2013 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-23263249

19.

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.

Peyrin-Biroulet, Laurent; Vermeire, Séverine; D'Haens, Geert; Panés, Julian; Dignass, Axel; Magro, Fernando; Nazar, Maciej; Le Bars, Manuela; Lahaye, Marjolein; Ni, Lioudmila; Bravatà, Ivana; Lavie, Frederic; Daperno, Marco; Lukás, Milan; Armuzzi, Alessandro; Löwenberg, Mark; Gaya, Daniel R; Danese, Silvio.

Aliment Pharmacol Ther ; 59(2): 175-185, 2024 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-38036946

20.

Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry.

Dryahina, Kseniya; Spanel, Patrik; Pospísilová, Veronika; Sovová, Kristýna; Hrdlicka, Ludek; Machková, Nadezda; Lukás, Milan; Smith, David.

Rapid Commun Mass Spectrom ; 27(17): 1983-92, 2013 Sep 15.

Artigo em Inglês | MEDLINE | ID: mdl-23939966

BVS Violência e Saúde

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Novel porcine model of Crohn's disease anastomotic stricture suitable for evaluation and training of advanced endoscopic techniques.

A novel postgraduate endoscopic course using a large animal model of secondary Crohn's disease stricture.

Treating inflammatory bowel diseases in the 21st century: individualized therapy and telemedicine.

Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Therapy for peptic ulcer disease.

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.

Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.

[Etiology and pathogenesis of inflammatory bowel diseases]. / Etiologie a patogeneze idiopatických strevních zánetu

Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.

Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.

Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry.